Background and Objectives Dosing algorithms for warfarin incorporate clinical and genetic factors but may not account for the numerous comorbidities affecting patients who start warfarin while hospitalized. We aimed to determine whether these algorithms perform differently when warfarin is initiated for inpatients compared with outpatients.
Abstract
Background and Objectives Dosing algorithms for warfarin incorporate clinical and genetic factors but may not account for the numerous comorbidities affecting patients who start warfarin while hospitalized. We aimed to determine whether these algorithms perform differently when warfarin is initiated for inpatients compared with outpatients.
Patients and Methods
We analyzed a prospective cohort of 1015 participants from the Clarification of Optimal Anticoagulation through Genetics (COAG) trial who were randomized to either pharmacogenetically or clinically guided warfarin dosing algorithms. Clinicians and participants were blinded to dose during the first 28 days. We compared groups, based on location at the time of the first warfarin dose request, in relation to the following outcomes: percentage of time in the therapeutic international normalized ratio (INR) range (PTTR) during the first 4 weeks, time to first therapeutic INR, time to maintenance dose, and the difference between predicted and observed maintenance doses.
Results A total of 527 participants started warfarin as inpatients and 488 as outpatients. There was no difference in PTTR based on location: 43.2 % for inpatient versus 47.4 % for outpatient initiation [mean adjusted difference -2.2 %; 95 % confidence interval (CI) -5.9 to 1.6]. Similarly, there were no differences in time to first therapeutic INR [hazard ratio (HR) 1.06; 95 % CI 0.91-1.24] or to maintenance dose (HR 0.96; 95 % CI 0.81-1.14). There was no evidence of interaction between study intervention (pharmacogenetically vs. clinically guided therapy) and location of initiation for these main outcomes. The difference between predicted and observed maintenance doses was similar for both locations.
Conclusion The warfarin dosing algorithms performed similarly for subjects who initiated warfarin as inpatients and outpatients, regardless of whether dosing was pharmacogenetically or clinically guided.
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Key Points
Dosing of warfarin remains complex, and existing algorithms designed to optimize dosing are derived predominantly from outpatient settings. Hospitalization at the time of warfarin initiation is associated with a greater burden of comorbidities than in the outpatient setting.
Despite these differences, this analysis of the COAG trial does not support the hypothesis that warfarin dosing algorithms perform worse when applied to inpatient compared with outpatient initiation of warfarin, regardless of whether dosing was based on a pharmacogenetically or a purely clinically guided algorithm.
Introduction
Warfarin is one of the most commonly prescribed medications, but is difficult to manage because of substantial variability in dose requirements across individuals. Despite the advent of newer anticoagulants for atrial fibrillation and deep venous thrombosis, warfarin continues to be widely used for these and many other clinical indications. The Clarification of Optimal Anticoagulation through Genetics (COAG) trial [1] demonstrated that initiation of warfarin therapy using algorithms based on genotype and clinical information (i.e., pharmacogenetically guided dosing) did not improve the time in the therapeutic international normalized ratio (INR) range compared with algorithms based on clinical information alone (i.e., clinically guided dosing). Prior studies derived the dose-initiation and dose-refinement algorithms used for the COAG trial, and demonstrated their utility in predicting maintenance dose [2, 3] . The algorithms incorporated clinical factors, including the following: age; race; body surface area; smoking status; history of diabetes; history of stroke; deep vein thrombosis (DVT) or pulmonary embolism (PE) as the primary indication for warfarin therapy; target INR; and major interacting medications (i.e., amiodarone or fluvastatin) [4, 5] . These dosing algorithms were primarily derived from outpatients treated with warfarin (personal e-mail communication, Brian Gage). There are numerous other comorbidities affecting inpatients that may be relevant to warfarin dosing but are not accounted for in the algorithms, such as recent surgery, reduced nutritional intake, and other major interacting medications, such as antibiotics [6, 7] . Conversely, monitoring of patients is more intensive in the hospital compared with outpatients, which may lessen the importance of a dosing algorithm [8] [9] [10] [11] [12] . We hypothesized that the algorithms would result in worse anticoagulation control and would not predict maintenance dose as well for those participants who initiated warfarin therapy as inpatients compared with those who started as outpatients. If so, this finding would have major repercussions on the use of these algorithms in clinical practice. In addition, we hypothesized that the effect of pharmacogenetically guided dosing on anticoagulation control would be more pronounced among inpatients than outpatients.
Methods
Our analysis was a secondary analysis of data collected during the COAG trial. The design and rationale of the COAG trial has been previously reported [13, 14] . Briefly, we randomly assigned 1015 patients at 18 clinical centers in the USA to initiate warfarin therapy using either a pharmacogenetically guided or a clinically guided dosing strategy, applied during the first 5 days of therapy. For each dosing strategy, a dose-initiation algorithm was used during the first 3 days of therapy [4] , and a dose revision algorithm was used on day 4, 5, or both [5] . The genetic variants included in the pharmacogenetic algorithm were cytochrome P-450, family 2, subfamily C, polypeptide 9 enzyme (CYP2C9) and vitamin K epoxide reductase complex 1 (VKORC1). Randomization was stratified by self-reported race (African-American vs. non-AfricanAmerican). All study participants and clinicians were blinded to the intervention and the dose of warfarin by the use of blinded encapsulated warfarin tablets during the first 4 weeks of therapy. The first INR mandated by the protocol was on day 4 or 5, though earlier INRs were permitted. The frequency of subsequent INR testing was guided by protocol for the first 28 days. The primary outcome was the percentage of time in therapeutic INR range (PTTR) during the initial 4 weeks. The PTTR was calculated using a standard linear interpolation method between successive INR values [15] .
For the present analysis, the location of warfarin initiation was classified as inpatient or outpatient on the basis of the location of the participant at the time of the first dose request. If location was missing at the time of the first dose request (n = 61), then location at the time of randomization was used. The primary outcome was the PTTR during the first 4 weeks. Secondary outcomes included time to first therapeutic INR, time to maintenance dose (defined as the first of two consecutive INR measurements in the therapeutic range without a dose change measured at least 1 week apart), and the difference between the predicted and observed maintenance doses.
Statistical Analysis
Participant characteristics at randomization were summarized using standard descriptive statistics and compared between those who initiated warfarin as outpatients versus inpatients. Primary and secondary outcomes were compared between inpatients and outpatients using regression models: linear regression for PTTR and Cox regression for time-to-event outcomes. All models adjusted for design variables (study intervention and stratification variables: self-reported race and clinical site) and participant characteristics found to differ between outpatient and inpatient groups (P \ 0.2). Models were additionally adjusted for genetic variants. Among all participants and by race (African-American or non-African-American), interaction terms between study intervention and location of initiation were used to determine average differences between intervention groups, stratified by location of initiation. Summary statistics including the partial R 2 from linear regression models that adjusted for design variables were used to evaluate the prediction accuracy of the algorithms for maintenance dose, among those participants who achieved maintenance dose.
We also performed a sensitivity analysis to account for the duration of time that participants were treated as inpatients, because those who start warfarin as inpatients on the day of discharge (and then immediately become outpatients) may be different from participants who remain as inpatients for several days. Instead of defining location as a binary variable, we calculated the proportion of days over the 5-day intervention period that participants were dosed as inpatients. For example, if a participant had the first outpatient dose request on day 1, the proportion was 0. If a participant had their first outpatient dose request on day 6, the proportion was 1. For outpatient initiation on days 2-5, the proportions were 0.2, 0.4, 0.6, and 0.8, respectively. The proportion of days dosed as an inpatient was entered as a continuous variable in regression analyses.
All statistical tests were two-sided. All analyses were conducted using R 3.0.1 (R Development Core Team, Vienna, Austria).
This analysis was specified prior to the analysis of the main COAG results. We expected that the proportions of subjects with inpatient versus outpatient initiation would be approximately equal, as were the two randomized groups in the overall study. Therefore, we anticipated that the power and detectable difference for this ancillary study would be similar to the overall COAG analysis, allowing for a minimum detectable difference of 5.5 % in mean PTTR between the two groups.
Results
A total of 1015 participants were randomized in the COAG trial, 527 as inpatients and 488 as outpatients. Participant characteristics according to location of warfarin initiation are summarized in Table 1 . Participants who started as inpatients were younger, were more likely to be AfricanAmerican, had greater body surface area, and were more likely to be current smokers. Inpatients were also more likely to have a history of heart failure or PE and less likely to have a history of DVT. Inpatients and outpatients Inpatients were also more likely to have current treatment with amiodarone or heparin at the time of randomization. There were no differences in CYP2C9 genetic variants but inpatients tended to have fewer variants in VKORC1. An INR was obtained on day 2 or 3 for 350 (66 %) of the inpatients and 60 (12 %) of the outpatients. At each visit during the first month of therapy, participants were asked if they missed any doses or took any extra doses in the prior week. The mean reported non-adherence across these visits was 5.5-11.6 % in the inpatient group and 4.5-10.1 % in the outpatient group. A total of 60 participants withdrew prior to completing the intervention and did not have an available PTTR, resulting in an analytic sample size of 955. There was no statistically significant difference in PTTR between participants on the basis of the location of warfarin initiation: 43.2 % for inpatient versus 47.4 % for outpatient initiation ( Table 2 ; Fig. 1 ). There was also no difference in PTTR in the adjusted models. Further, the percentage of time that the INR was low (i.e., \2.0) or high (i.e., [3.0) was also highly similar in both groups. Similarly, there were no significant differences in time to first therapeutic INR (8 vs. 9 days) or time to maintenance dose (32 vs. 29 days) ( Table 2 ; Fig. 2a, b) .
There was no evidence of interaction between study intervention (pharmacogenetically guided vs. clinically guided therapy) and location of warfarin initiation for Month   484  212  120  82  51  30  14   469  198  111  75  44  31  10 Number at risk Fig. 2 Kaplan-Meier curves that display the a probability of achieving a therapeutic INR during the first 4 weeks of warfarin therapy and b probability of achieving maintenance dose during the 6-month study period for inpatients and outpatients. INR international normalized ratio PTTR, time to first therapeutic INR, or time to maintenance dose. Among all participants and by race, average differences between intervention groups were similar between inpatient and outpatient initiations (see online resource 1, Supplementary Tables 1-3 ). In sensitivity analyses that accounted for the time spent as an inpatient during the intervention period, there were again no differences in these outcomes (Supplementary Table 4) . The relationship between the predicted and observed maintenance doses is summarized in Table 3 . The doseinitiation algorithm predicted maintenance dose slightly better for participants who started warfarin as inpatients than those who started as outpatients in the clinically guided arm only (R 2 0.28 vs. 0.19; rank correlation 0.61 vs. 0.46). However, no differences were observed for the doserevision algorithm employed on day 4 and/or 5.
Discussion
Numerous clinical factors have a substantial impact on the dosing of warfarin [4, 5, 16] . Only a select few of these factors have been incorporated into standardized algorithms, namely age, race, body size, diabetes, current smoking, indication for anticoagulation, and concomitant use of two specific interacting medications (amiodarone or fluvastatin). However, the metabolism of warfarin is well known to be affected by diet, hundreds of commonly used medications and nutriceuticals, alcohol, and thyroid disease [16] . Moreover, no model for predicting warfarin dosing has been able to account for more than about 50 % of the inter-individual variability [5, 17] , suggesting the existence of other unknown environmental or genetic factors.
We hypothesized that the location of warfarin initiation might serve as a proxy for a host of unmeasured clinical factors that impact dosing, since inpatients are more likely to be acutely or recently ill, with altered nutritional and metabolic status, and more likely to be treated with interacting medications than patients who start warfarin as outpatients. Prior studies have shown that inpatient warfarin dosing may be enhanced by a pharmacist or multidisciplinary team approach [8] [9] [10] [11] [12] , suggesting the need for clinical judgment over the use of a standard algorithm. However, we were unable to support these hypotheses, as there were no differences in PTTR during the first 28 days, proportions of INR below and above the therapeutic range, time to first therapeutic INR, time to maintenance dose, or prediction of maintenance dose that were related to location of warfarin initiation. Of these measures, time to first therapeutic INR would likely be the most sensitive to these early unmeasured factors, but we found no difference between groups. Further, we expected the differences between groups to be more pronounced for participants who spent more time as inpatients, but again found none.
Several explanations are possible. The simplest is that the differences expected between groups were too inconsequential to impact any measures of warfarin dosing during the first 4 weeks. Alternatively, it is possible that some of the clinical factors in the algorithm already account for these differences. For example, an inpatient with a stroke may have altered anabolic metabolism and nutritional intake (not accounted for in the algorithms), but might have a reduction in dose due to weight loss (and a concomitant reduction in body surface area, which is included in the dosing algorithm), and that may be sufficient without further adjustment.
The COAG trial specifically addressed the incremental effect of using genetics in addition to clinical information in the setting of standardized, post-initiation dose titration. The trial did not compare genotype-based dosing with usual care or a fixed initial dose (e.g., 5 mg/day). It therefore remains uncertain whether the location of warfarin initiation might be an important consideration in those contexts [6, 7, 18] .
Conclusion
This analysis of the COAG trial does not support the hypothesis that warfarin dosing algorithms perform worse when applied to inpatient compared with outpatient initiation of warfarin, regardless of whether dosing was based on a pharmacogenetically or a purely clinically guided algorithm. Future studies should continue to attempt to identify factors that impact warfarin dosing but are not currently incorporated into existing dosing algorithms.
